10 AM ET, 7 AM PT
Dennis Verzijl, Ph.D., Genmab
Craig Tin, Director, Regional Marketing, Pall ForteBio
Label-free technologies provide critical information for the drug discovery process, from the screening of specific drug target binding interactions, to measuring the affinity of that binding. When used with purified proteins or membrane fractions, these assays are limited in providing rich insight into the complex milieu of cellular response signaling molecules. Bio-Layer Interferometry (BLI) has recently been demonstrated to monitor binding interactions in real time with live cells, creating a novel cell-based BLI that has the potential to increase the versatility of label-free assays in screening labs for finding hit that rely on more complex signal transduction.
This webinar will describe the development of a cell-based BLI assay on the Pall-ForteBio Octet HTX system and explore how high-throughput label-free assays can streamline the drug discovery process.